A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

This study is testing whether adding a drug called orelabrutinib (a targeted therapy that blocks a cancer-promoting protein) to a standard chemotherapy regimen (R-CHOP) improves outcomes for people newly diagnosed with double expression diffuse large B-cell lymphoma (DE-DLBCL), an aggressive type of blood cancer. **You may be eligible if...** - You are aged 18–70 - You have been newly diagnosed with double expression DLBCL - Your cancer is at stage II–IV (spread beyond one lymph node area) - You are in reasonable health (ECOG 0–2) - You have a life expectancy of at least 3 months - Your lab results (blood counts, organ function) meet required standards **You may NOT be eligible if...** - The lymphoma has spread to the brain or spinal fluid - You have uncontrolled heart, blood clotting, or autoimmune diseases - You have uncontrolled infections (including hepatitis B or C, or HIV) - You are being considered for a transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.